Skip to main content
Equibles
AZTR logo

AZTR · Azitra, Inc. · Metrics

Track AZTR — free

Use AZTR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AZTR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.13 +0.00 (+2.72%) At close · Oct 2
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions and events create substantial doubt about the ability of the Company to continue as a going concern for twelve months from the date that the financial statements are available to be issued. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$7.91M
Shares
60.60M
Volume · Oct 2 825.84K Avg daily vol (3M) 1.74M

AZTR metrics

56 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.13
Market cap
$7.91M

Price action

20 metrics
Price change (1W)
-21.4%
Price change (30D)
-26.7%
Price change (3M)
-12.6%
Price change (6M)
-43.8%
Price change (YTD)
-50.2%
Price change (1Y)
-82.1%
Trailing year
Price change (5Y)
—
52-week high
$0.79
52-week low
$0.13
Change from 52-week high
-83.3%
Change from 52-week low
+5.6%
Annualized volatility
120.6%
Annualized volatility (3M)
79.9%
Beta
0.0
RSI (14D)
35.3
Price vs SMA 50
-13.7%
Price vs SMA 200
-34.8%
Avg volume (3M)
1.74M
Relative volume
0.5
Average dollar volume
$257,002

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
60.60M

Valuation

12 metrics
P / E (TTM)
2.2
Trailing earnings · reciprocal yield 45.5%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.1
reciprocal yield 92.7%
FCF yield
-141.2%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-155.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-13

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$12.35M
Net income (TTM)
−$12.27M
Trailing 12 months
Diluted EPS (TTM)
$0.06
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.35

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+689.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-167.3%
Return on assets
-137.6%
Debt / equity
—
Current ratio
4.9
EBITDA (TTM)
−$12.20M
Free cash flow (TTM)
−$11.17M
Quick ratio
4.9
Interest coverage
-1,164.7
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$6.73M
Latest balance sheet
Cash & equivalents
$6.73M
Total assets
$8.92M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$11.11M
Capital expenditures (TTM)
$67,593
R&D (TTM)
$5.10M
SG&A (TTM)
—
Stock compensation (TTM)
$33,865
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
14
13F filer change QoQ
+7
Institutional ownership
32.0%

Short interest

3 metrics
Short interest
1.2%
Latest settlement · 1.4 days to cover
Days to cover
1.4d
Short-squeeze score
41 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1701478 CUSIP 05479L302 Visit website Investor relations